Business Overview
American HealthCare Capital is pleased to exclusively introduce a premier, award-winning medically supervised weight loss and regenerative wellness clinic located in one of the most affluent and dense aesthetics markets in the Southwest. Established as an agile, low-overhead operation, the clinic specializes in a comprehensive, doctor-supervised service array. Turn-key modalities include FDA-approved GLP-1 therapies (Compounded Semaglutide and Tirzepatide), advanced peptide protocols, customized IV nutrient therapy, non-invasive body contouring (red-light and muscle stimulation), body composition analysis, and anti-aging medicine. The platform has serviced over 3,000 unique patients since inception and controls a proprietary marketing database containing over 14,000 historical patient and lead records.
The practice operates out of a modernized, fully equipped facility configured with multiple private treatment rooms and an executive consultation space, positioned under a market-favorable lease.
Operational & Payer Profile
The clinic functions under a highly insulated 100% private-pay / cash-pay operational framework, completely eliminating Medicare, Medicaid, and commercial insurance billing dependencies, credentialing delays, and auditing risk. In January 2026, the clinic successfully shifted a portion of its transactional patient volume into a tiered monthly membership program. In less than five months, this auto-pay initiative has scaled to 30 active recurring members generating approximately $14,500 per month in predictable revenue, establishing a baseline run-rate of $174,000 in annualized recurring revenue. The clinic handles an active, consistent baseline volume of 75 to 100 unique weight-loss patients receiving specialized clinical treatments each month.
Financial Performance & Margin Drivers
The business exhibits stable historical earnings paired with an explosive, high-margin expansion trajectory in 2026. For fiscal year 2024, the clinic achieved gross service revenues of more than $594,000, expanding to over $615,000 for fiscal year 2025. After recasting corporate statements for owner compensation and discretionary write-offs, the operation produced consistent, CPA-validated Seller’s Discretionary Earnings (SDE) of approximately $107,000 in 2024 and 2025. Driven by the new membership architecture and a structural 75% cost reduction per vial in pharmaceutical input supplies negotiated in late 2025, current fiscal year 2026 earnings are tracking approximately 42% above historical baselines, annualizing at an Adjusted SDE of over $150,000.
Infrastructure & Transition
There is a full complement of staff that includes management and clinical practitioners who are fully expected to remain with the business post-acquisition. The current owner is pursuing a divestiture to accommodate retirement but will provide an extended transitional oversight period to guarantee operational continuity and successful clinical knowledge transfer.
Asking Price
The owner is open to discussing valuation and will consider competitive offers.